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A major clinical dilemma in the management of patients with early stage breast cancer is 
determining which patients are at risk of subsequent recurrence so that these patients may be 
offered adjuvant therapies. Currently, the major prognostic factors used in determining 
prognosis including nodal status and tumour size fail to identify up to 30% of patients 
classified as having low risk disease who subsequently recur with breast cancer. Therefore, 
there is a great need for new methodologies that can sensitively and specifically identify 
disseminated disease. 
During this study, the major aims were to use immunobead-based and methylation-based 
methods for the detection of occult disseminated disease in peripheral blood samples obtained 
from breast cancer patients. Firstly, an RT-PCR assay was developed that identified a panel of 
gene specific markers that could be used for sensitive and specific detection of any circulating 
epithelial cells with minimal risk of false positive results from contaminating haematopoietic 
compartment cells. These gene markers were used to assess breast cancer patients using 
immunobead enrichment prior to RT-PCR (IB RT-PCR) and resulted in the detection of 
circulating epithelial cells in 21157 peripheral blood samples. Importantly, some of these 
patients had been deemed lymph node negative and at low risk of relapse. 
Furthermore, it was decided to screen for gene promoter region methylation in freely 
circulating DNA in the plasma fraction, and in DNA from the nuclei of epithelial cells 
captured using the immunomagnetic enrichment method. The analysis of gene loci 
methylation of patient samples was conducted concurrently with the analysis of the frequency 
of gene loci methylation in mononuclear cells from normal individuals. Surprisingly, a high 
proportion of normal individuals were methylated at high frequency at gene loci that have 
previously been reported to be tumour specific. This finding had implications for the 
concurrent study using methylation as a marker of occult disseminated disease in breast 
cancer patients. 
The analysis of blood samples using the methodology presented in this thesis for the early 
detection of breast cancer dissemination, has the potential to be developed to a point where it 
can be introduced into the clinical setting. Once fully developed and validated, this minimally 
invasive methodology, that causes little discomfort to the patient, could help to improve 
breast cancer staging, and provide important prognostic information ensuring the 
identification of those early stage breast cancer patients with the greatest risk of relapse and in 
most need of adjuvant therapies. 
